AKT1 and neoplasm: Pre-clinical trials have shown that the schedule of gemcitabine followed by gefitinib might improve efficacy compared to gemcitabine alone, because this schedule resulted in decreased AKT phosphorylation, increased poly(ADP-ribose) polymerase cleavage, and increased tumor cell apoptosis in the treatment of head and neck carcinoma [18].